In this issue of Blood , [Burnett et al][1] present the results of United Kingdom (UK) National Cancer Research Council Acute Myeloid Leukemia 17 (NCRI AML17), a randomized comparison of daunorubicin (90 vs 60 mg/m2) in induction in 1206 patients with acute myeloid leukemia (AML), showing no benefit
No takes yet. Share an insight, caveat, or question.
Hugo F. Fernández (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: